期刊文献+

抗VEGF药物治疗血管源性眼病的基础与临床研究进展 被引量:15

Advance of substructure and clinical research about anti-VEGF therapy for ocular vascular disease
下载PDF
导出
摘要 许多人类血管源性眼病均与血管内皮生长因子(VEGF)有关。近年来玻璃体腔注射抗VEGF药物治疗血管源性眼病逐渐应用于临床,就macugen,lucentis和avastin三种抗VEGF药物的基础研究、临床应用进展及不良反应情况进行综述,从生物学特性、临床疗效及应用前景等方面分析比较三种药物的共同点与特异性。 Vascular endothelial growth factor (VEGF) had been implicated as the major factor in the induction of ocular vascular disease, such as advanced age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), neovascularization secondary to retinal vein occlusion ( RVO ) , etc.. Intravitreal anti-VEGF injection had been used for treating ocular vascular disease generally, especially for AMD complicated with choroidal neovascularization. Application of VEGF can stabilize visual acuity and even improve visual acuity. The advance in basic research, clinical application and adverse effects of anti-VEGF therapy including macugen,lucentis and avastin, are reviewed. The biology feature, clinic efficacy and perspection of the three drugs are analyzed and compared.
出处 《眼科研究》 CSCD 北大核心 2008年第9期708-712,共5页 Chinese Ophthalmic Research
关键词 血管内皮生长因子 MACUGEN LUCENTIS AVASTIN 玻璃体腔注药 VEGF macugen lucentis avastin intravitreal injection
  • 相关文献

参考文献38

  • 1Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice over expressing vascular endothelial growth factor in the retinal pigment epithelium [ J ]. Am J Pathol, 2001, 158 ( 3 ) : 1161 - 1172
  • 2Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration [ J ]. N Engl J Med, 2004, 351 ( 27 ) : 2805 - 2816
  • 3Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab : Phase Ⅲ clinical trial results [ J ]. Ophthalmol Clin North Am,2006,19 ( 3 ) : 361 - 372
  • 4Spaide RF,Laud K,Fine HF,et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration [J]. Retina ,2006,26 (4): 383 - 390
  • 5Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments [ J ]. Br J Ophthalmol, 2006,90 ( 12 ) : 1542 - 1547
  • 6Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization [ J]. Mol Vis,2002,8:119 -126
  • 7Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration [ J]. Can J Ophthalmol, 2005,40 (3):352-368
  • 8Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection [ J ]. Bioessays, 2004,26 ( 9 ) : 943 - 954
  • 9Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization [ J ]. J Exp Med,2003,198 ( 3 ) : 483 - 489
  • 10Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer ( EYEO01 ) for the treatment of exudative age-related macular degeneration [ J ]. Retina, 2002,22 ( 2 ) : 143 - 152

同被引文献154

引证文献15

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部